PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsIpilimumab
Yervoy(ipilimumab)
Yervoy (ipilimumab) is an antibody pharmaceutical. Ipilimumab was first approved as Yervoy on 2011-03-25. It is used to treat melanoma in the USA. It has been approved in Europe to treat colorectal neoplasms, malignant mesothelioma, melanoma, non-small-cell lung carcinoma, and renal cell carcinoma. The pharmaceutical is active against cytotoxic T-lymphocyte protein 4.
Download report
Favorite
Drugs Approved for Childhood Cancers
BMS
Top 200 Pharmaceuticals by Retail Sales
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
digestive system diseasesD004066
respiratory tract diseasesD012140
urogenital diseasesD000091642
Trade Name
FDA
EMA
Yervoy
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Ipilimumab
Tradename
Proper name
Company
Number
Date
Products
YervoyipilimumabBristol Myers SquibbN-125377 RX2011-03-25
2 products
Labels
FDA
EMA
Brand Name
Status
Last Update
yervoyBiologic Licensing Application2025-05-28
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
melanoma—D008545—
Agency Specific
FDA
EMA
Expiration
Code
ipilimumab, Yervoy, Bristol-Myers Squibb Company
2027-10-02Orphan excl.
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01F: Monoclonal antibodies and antibody drug conjugates
— L01FX: Other monoclonal antibodies and antibody drug conjugates in atc
— L01FX04: Ipilimumab
HCPCS
Code
Description
J9228
Injection, ipilimumab, 1 mg
Clinical
Clinical Trials
952 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
MelanomaD008545——12317925453330
NeoplasmsD009369—C8083775214140
Renal cell carcinomaD002292EFO_0000376—3243921690
Neoplasm metastasisD009362EFO_0009708—363141358
Lung neoplasmsD008175—C34.90162471948
Kidney neoplasmsD007680EFO_0003865C6481062932
Skin neoplasmsD012878EFO_0004198C4491031322
ImmunotherapyD007167——11—146
OncogenesD009857—————1—1
RadiotherapyD011878—————1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Non-small-cell lung carcinomaD002289——426317—16113
Prostatic neoplasmsD011471—C6115253—140
Pancreatic neoplasmsD010190EFO_0003860C2521211—236
Colorectal neoplasmsD015179——19214—236
Hepatocellular carcinomaD006528—C22.016196—131
Uveal neoplasmsD014604EFO_1001230—15173——28
Liver neoplasmsD008113EFO_1001513C22.013176——27
Brain neoplasmsD001932EFO_0003833C719191—127
Breast neoplasmsD001943EFO_0003869C5013151—126
Cutaneous malignant melanomaD000096142——12161—126
Show 27 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Transitional cell carcinomaD002295——1212——119
Triple negative breast neoplasmsD064726——1110———15
Non-hodgkin lymphomaD008228—C85.9106———13
Urologic neoplasmsD014571—C64-C6896——112
LymphomaD008223—C85.9105———12
Myelodysplastic syndromesD009190—D4692———11
Myeloid leukemia acuteD015470—C92.0101———11
Multiple myelomaD009101—C90.086———11
B-cell chronic lymphocytic leukemiaD015451—C91.192———9
Castration-resistant prostatic neoplasmsD064129——44———8
Show 144 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Myeloproliferative disordersD009196—D47.15————5
Bcr-abl positive chronic myelogenous leukemiaD015464EFO_0000340—4————4
Autoimmune diseasesD001327EFO_0000540M30-M361———34
Leukemia myeloid chronic atypical bcr-abl negativeD054438—C92.23————3
T-cell lymphoma cutaneousD016410—C84.A3————3
Motor activityD009043EFO_0003940—1———23
Primary myelofibrosisD055728—D47.42————2
Myelodysplastic-myeloproliferative diseasesD054437——2————2
Healthy volunteers/patients———1———12
Large-cell lymphoma anaplasticD017728—C84.62————2
Show 52 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
MyocarditisD009205—I51.4————33
Drug-related side effects and adverse reactionsD064420—T88.7————33
Heart diseasesD006331EFO_0003777I51.9————22
MicrobiotaD064307——————22
MetagenomeD054892——————22
Multiple primary neoplasmsD009378——————22
Cardiovascular diseasesD002318EFO_0000319I98————11
CardiomyopathiesD009202EFO_0000318I42————11
PericarditisD010493EFO_0007427I30————11
VasculitisD014657EFO_0006803M31————11
Show 11 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameIpilimumab
INNipilimumab
Description
Ipilimumab (human mab)
Classification
Antibody
Drug classmonoclonal antibodies
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
>7SU0:H,I|Fab heavy chain (PCA)VQLVESGGGVVQPGRSLRLSCAASGFTFSHYTMHWVRQAPGKGLEWVTFISYDGHNKYYADSVKGRFTISRDNSK NTLYLQMNSLRAEDTAIYYCARTGWLGPFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVT VSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCGGHHHHHH >7SU0:L,M|Fab light chain EIVLTQSPGTLSLSPGERATLSCRASQEVGESELAWYQQKPGQAPRLLIYGAFSRATGIPDRFSGSGSGTDFTLTISRLE PEDFAVYYCQQYGSSPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNS QESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
Identifiers
PDB5TRU, 5XJ3, 6JC2, 6RP8, 7SU0, 7SU1
CAS-ID—
RxCUI—
ChEMBL IDCHEMBL1789844
ChEBI ID—
PubChem CID—
DrugBankDB06186
UNII ID6T8C155666 (ChemIDplus, GSRS)
Target
Agency Approved
CTLA4
CTLA4
Organism
Homo sapiens
Gene name
CTLA4
Gene synonyms
CD152
NCBI Gene ID
1493
Protein name
cytotoxic T-lymphocyte protein 4
Protein synonyms
CD152, celiac disease 3, CTLA-4, cytotoxic T lymphocyte associated antigen 4 short spliced form, Cytotoxic T-lymphocyte-associated antigen 4, cytotoxic T-lymphocyte-associated serine esterase-4, gluten-sensitive enteropathy, insulin-dependent diabetes mellitus 12, ligand and transmembrane spliced cytotoxic T lymphocyte associated antigen 4
Uniprot ID
P16410
Mouse ortholog
Ctla4 (12477)
cytotoxic T-lymphocyte protein 4 (P09793)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Yervoy – Bristol Myers Squibb
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 9,999 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
45,062 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use